SLC22A2基因变异与多替拉韦谷浓度同HIV感染者精神症状相关
该横断面队列纳入203例使用含多替拉韦方案的HIV感染者,检测SLC22A2 808C→A多态性及多替拉韦谷浓度,用症状自评量表-90-R、自评问卷和迷你国际神经精神访谈评估当前神经精神症状。多因素logistic回归显示,SLC22A2 CA基因型与异常总体严重指数、焦虑、敌意及中重度头痛独立相关,多替拉韦谷浓度与敌意和精神病性症状相关。OCT2编码基因变异与较高多替拉韦谷浓度单独或协同关联多替拉韦治疗期间的一组神经精神症状。
要点
- SLC22A2 CA基因型与异常GSI、焦虑、敌意及中重度头痛独立相关。
- 多替拉韦谷浓度第四分位较第一分位与敌意和精神病性症状相关。
- 其他神经精神症状与SLC22A2多态性或多替拉韦谷浓度无关。
核心结论
- OCT2编码基因SLC22A2变异与较高多替拉韦谷浓度单独或协同关联多替拉韦治疗期间的一组神经精神症状。
研究设计与样本
- 横断面队列分析203例使用含多替拉韦方案的HIV阳性患者,检测SLC22A2 808C→A等位基因判别和多替拉韦谷浓度,并用症状自评量表-90-R、自评问卷和迷你国际神经精神访谈评估当前神经精神症状。
- 采用多因素logistic回归探讨多替拉韦谷浓度和SLC22A2基因变异对神经精神症状的影响。
主要发现
- SLC22A2 CA基因型与异常总体严重指数独立相关(aOR 2.43;P=0.072)。
- SLC22A2 CA基因型与焦虑(aOR 2.61;P=0.044)、敌意(aOR 3.76;P=0.012)及中重度头痛(aOR 5.55;P=0.037)独立相关。
- 多替拉韦谷浓度第四分位较第一分位与敌意(aOR 6.70;P=0.007)和精神病性症状(aOR 19.01;P=0.008)相关。
- 其他神经精神症状与SLC22A2多态性或多替拉韦谷浓度无关联。
临床怎么用
- 对使用多替拉韦的HIV感染者出现焦虑、敌意、头痛或精神病性症状时,可考虑评估SLC22A2 808C→A多态性及多替拉韦谷浓度。
局限性
- 横断面设计无法确定因果关系。
- SLC22A2 CA基因型与异常GSI的关联P=0.072,未达传统统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neuropsychiatric symptoms (NPs) have been reported with dolutegravir use. We hypothesized that increasing dolutegravir trough concentrations (Ctrough) and/or polymorphism in the SLC22A2 gene, encoding the organic cation transporter-2 (OCT2), which is involved in monoamine clearance in the CNS and is inhibited by dolutegravir, might be associated with NPs. METHODS: A cross-sectional cohort of HIV-positive patients treated with a dolutegravir-containing regimen underwent determination of allelic discrimination for SLC22A2 808 C → A polymorphism and dolutegravir Ctrough. The Symptom Checklist-90-R [investigating 10 psychiatric dimensions and reporting a general severity index (GSI)], a self-reported questionnaire and the Mini-International Neuropsychiatric Interview were offered to investigate current NPs. The effects of dolutegravir Ctrough and the SLC22A2 gene variant on NPs were explored by multivariable logistic regression. RESULTS: A cohort of 203 patients was analysed: 71.4% were male, with median age 51 years and 11 years of ART exposure. Median time on dolutegravir was 18 months. Dolutegravir was associated with different antiretroviral combinations (mainly lamivudine, 38.9%, and abacavir/lamivudine, 35.5%). SLC22A2 CA genotype was independently associated with an abnormal GSI [adjusted OR (aOR) 2.43; P = 0.072], anxiety (aOR 2.61; P = 0.044), hostility (aOR 3.76; P = 0.012) and with moderate to severe headache (aOR 5.55; P = 0.037), and dolutegravir Ctrough was associated with hostility (fourth versus first quartile aOR 6.70; P = 0.007) and psychoticism (fourth versus first quartile aOR 19.01; P = 0.008). Other NPs were not associated with SLC22A2 polymorphism or dolutegravir Ctrough. CONCLUSIONS: A variant of the OCT2-encoding gene, in addition to or in synergy with higher dolutegravir Ctrough, is associated with a set of NPs observed during dolutegravir therapy.
引用
- Borghetti A, Calcagno A, Lombardi F, et al. SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. J Antimicrob Chemother. 2019. PMID: 30561642. doi:10.1093/jac/dky508
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。